Wockhardt Q2 FY27 Share Price & Earnings Call Analysis
Part of: Nifty Smallcap 250 · Nifty Pharma · Nifty Smallcap 50 · NIFTY Smallcap 100 · Nifty MidSmallcap 400 · Nifty 500 · +1 more
- Market cap
- ₹32,620 Cr
- P/E
- 81.61
- ROE
- 6.11%
- PEG
- 1.88
- Price to sales
- 8.70
- Debt to equity
- 0.43
- 52W high / low
- ₹2,330 / ₹1,100
- Sales growth (5Y)
- 4.49%
- EBITDA margin
- 20.45%
- Net profit margin
- 8.01%
- Promoter holding
- 49.33%
- Sales (last year)
- ₹3,751 Cr
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments). [1]
Guidance scorecard · Q2 FY27 call
What Wockhardt's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ4 FY26 call
20–40%- Slow initial increase in revenue from new molecules like Zaynich, with a hockey-stick growth trajectory expected after 12-18 months.
- Significant market share goal of about 20-25% of resistant cases long-term.
- Biosimilar business to double within 24 to 36 months driven by capacity expansion and pipeline product launches.
- Capex of INR 200-300 crores planned over next three years, mainly in biologicals capacity.
- Initial 12-18 months of slight loss or neutral profitability expected during market organization establishment for Zaynich, followed by strong profitability growth.
- Overall company growth inherent due to multiple molecules without needing acquisitions.
- India biosimilar market opportunity estimated at $6-7 billion.
2 more points from Wockhardt's call on revenue
Create a free account to keep reading this call
MarginsQ4 FY26 call
FlatSee what Wockhardt said on margins — free account, 30 seconds.
CapexQ4 FY26 call
Planned- Planned capex over next three years: INR 200 to 300 crores, mainly for expanding biologicals capacity.
- Investment in increasing biosimilar capacity, aiming to double capacity within 12 to 15 months.
- Continued R&D spends at a consistent percentage of sales to support product pipeline development.
- Focus on building a new business model and organizational capabilities for commercialization of innovative drugs like Zaynich, involving upfront revenue costs rather than capex.
2 more points from Wockhardt's call on capex
Create a free account to keep reading this call
FundraisingQ4 FY26 call
See what Wockhardt said on fundraising — free account, 30 seconds.
Order bookQ4 FY26 call
Ask what Wockhardt said on the order book →
Full Q4 FY26 analysisRanges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹480 Cr | 19.1 | |
| 2 | 40%+ | Up 0–2% | ₹212 Cr | 16.1 | |
| 3 | 40%+ | Flat | ₹18,347 Cr | — | |
| 4 | 40%+ | Flat | ₹8,418 Cr | 32.3 | |
| 5 | 40%+ | Flat | ₹4,268 Cr | — | |
| 6 | 40%+ | Flat | ₹40 Cr | — |
Sign up free to see every company in the sector ranking and track Wockhardt.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Wockhardt
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Wockhardt
Shareholding breakup across reporting periods.
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters + | 54.93% | 51.60% | 51.99% | 51.99% | 49.09% | 49.09% | 49.09% | 49.09% | 49.09% | 49.09% | 49.09% | 49.33% |
| FIIs + | 4.18% | 5.49% | 5.94% | 6.70% | 6.54% | 6.82% | 7.29% | 7.10% | 7.00% | 7.09% | 7.23% | 7.02% |
| DIIs + | 0.30% | 4.82% | 4.45% | 5.08% | 9.82% | 10.58% | 11.00% | 11.00% | 10.55% | 10.96% | 9.24% | 9.00% |
| Government + | 0.00% | 0.01% | 0.01% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.04% | 0.02% | 0.01% |
| Public + | 40.59% | 38.06% | 37.62% | 36.21% | 34.54% | 33.50% | 32.60% | 32.79% | 33.36% | 32.84% | 34.44% | 34.64% |
| No. of Shareholders | 1,61,813 | 1,46,138 | 1,40,391 | 1,38,142 | 1,42,710 | 1,41,799 | 1,46,918 | 1,37,946 | 1,42,274 | 1,39,016 | 1,66,518 | 1,73,116 |
Pros & Cons
Wockhardt
Key positives and risks surfaced from the company insights section.
- Stock is trading at 5.98 times its book value
- The company has delivered a poor sales growth of 4.49% over past five years.
- Company has a low return on equity of -1.43% over last 3 years.
- Promoter holding has decreased over last 3 years: -5.81%
- Stock is trading at 5.98 times its book value
- The company has delivered a poor sales growth of 4.49% over past five years.
- Company has a low return on equity of -1.43% over last 3 years.
- Promoter holding has decreased over last 3 years: -5.81%
Financials of Wockhardt
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 753 | 701 | 700 | 739 | 809 | 721 | 743 | 738 | 782 | 888 | 965 | 929 | 969 |
| YoY Sales growth | +11% | +0% | +3% | +15% | +7% | +3% | +6% | -0% | -3% | +23% | +30% | +26% | +24% |
| Expenses + | 681 | 664 | 759 | 648 | 699 | 593 | 679 | 666 | 604 | 711 | 740 | 737 | 796 |
| Operating Profit | 72 | 37 | -59 | 91 | 110 | 128 | 64 | 72 | 178 | 177 | 225 | 192 | 173 |
| OPM % | 10% | 5% | -8% | 12% | 14% | 18% | 9% | 10% | 23% | 20% | 23% | 21% | 18% |
| Other Income + | 24 | 8 | 10 | 30 | 9 | 8 | 15 | -77 | 21 | 15 | 67 | 31 | 11 |
| Interest | 76 | 77 | 73 | 73 | 73 | 60 | 48 | 48 | 55 | 60 | 50 | 52 | 56 |
| Depreciation | 55 | 55 | 58 | 54 | 55 | 55 | 53 | 56 | 53 | 65 | 53 | 55 | 55 |
| Profit before tax | -35 | -87 | -180 | -6 | -9 | 21 | -22 | -109 | 91 | 67 | 189 | 116 | 73 |
| Tax % | 109% | -1% | -2% | 167% | 78% | 5% | 105% | -1% | 10% | 9% | 13% | 8% | 0% |
| Net Profit + | -73 | -86 | -177 | -16 | -16 | 20 | -45 | -108 | 82 | 61 | 164 | 107 | 73 |
| EPS in Rs | -5.34 | -5.76 | -11.02 | -0.91 | -1.43 | 0.86 | -1.54 | -5.54 | 4.80 | 3.63 | 10.22 | 6.52 | 4.86 |
Financials of Wockhardt
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 4,482 | 4,453 | 4,015 | 3,937 | 3,566 | 2,844 | 2,708 | 3,230 | 2,651 | 2,798 | 3,012 | 3,373 | 3,751 |
| Sales growth | -7% | -1% | -10% | -2% | -9% | -20% | -5% | +19% | -18% | +6% | +8% | +12% | +26% |
| Expenses + | 3,772 | 3,959 | 4,002 | 3,935 | 3,604 | 2,725 | 2,771 | 2,932 | 2,549 | 2,707 | 2,619 | 2,721 | 2,984 |
| Operating Profit | 709 | 494 | 13 | 2 | -38 | 119 | -63 | 298 | 102 | 91 | 393 | 652 | 767 |
| OPM % | 16% | 11% | 0.3% | 0.1% | -1.1% | 4.2% | -2.3% | 9% | 3.9% | 3.2% | 13% | 19% | 20% |
| Other Income + | 67 | 66 | 114 | -238 | 116 | 133 | 975 | -163 | -173 | 17 | 62 | 26 | 124 |
| Interest | 55 | 129 | 225 | 255 | 265 | 276 | 249 | 299 | 302 | 305 | 254 | 213 | 218 |
| Depreciation | 145 | 142 | 149 | 150 | 164 | 224 | 246 | 247 | 251 | 223 | 217 | 227 | 228 |
| Profit before tax | 575 | 289 | -247 | -641 | -351 | -247 | 417 | -411 | -624 | -420 | -16 | 238 | 445 |
| Tax % | 28% | 13% | -9% | 4% | -38% | -82% | -65% | -32% | -0% | 12% | 256% | 16% | |
| Net Profit + | 413 | 252 | -226 | -667 | -217 | -43 | 688 | -279 | -621 | -472 | -57 | 199 | 405 |
| EPS in Rs | 33.91 | 20.91 | -16.32 | -50.69 | -16.20 | -5.76 | 57.07 | -16.94 | -38.80 | -30.18 | -2.89 | 13.11 | 25.23 |
| Dividend Payout % | 54% | 0% | -56% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Wockhardt
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 55 | 55 | 55 | 55 | 55 | 55 | 55 | 72 | 72 | 77 | 81 | 81 | 81 |
| Reserves | 3,362 | 3,720 | 3,281 | 2,797 | 2,619 | 2,616 | 3,321 | 3,777 | 3,282 | 3,282 | 4,272 | 4,859 | 5,077 |
| Borrowings + | 2,309 | 2,677 | 4,160 | 3,748 | 3,375 | 3,582 | 2,674 | 2,198 | 2,184 | 2,356 | 2,021 | 2,233 | 2,238 |
| Other Liabilities + | 1,213 | 1,622 | 1,486 | 1,528 | 1,764 | 1,894 | 1,696 | 2,168 | 2,113 | 1,899 | 1,726 | 1,405 | 1,506 |
| Total Liabilities | 6,939 | 8,074 | 8,982 | 8,128 | 7,813 | 8,148 | 7,746 | 8,215 | 7,651 | 7,614 | 8,100 | 8,578 | 8,902 |
| Fixed Assets + | 2,123 | 2,809 | 2,773 | 2,888 | 3,058 | 3,502 | 3,343 | 3,462 | 3,042 | 2,881 | 2,736 | 2,791 | 4,655 |
| CWIP | 1,007 | 1,036 | 1,244 | 1,433 | 1,445 | 1,585 | 1,379 | 1,342 | 1,539 | 1,722 | 2,033 | 2,379 | 676 |
| Investments | 341 | 0 | 563 | 214 | 0 | 0 | 0 | 0 | 0 | 0 | 422 | 412 | 117 |
| Other Assets + | 3,468 | 4,228 | 4,403 | 3,593 | 3,309 | 3,060 | 3,024 | 3,411 | 3,070 | 3,011 | 2,909 | 2,996 | 3,454 |
| Total Assets | 6,939 | 8,074 | 8,982 | 8,128 | 7,813 | 8,148 | 7,746 | 8,215 | 7,651 | 7,614 | 8,100 | 8,578 | 8,902 |
Financials of Wockhardt
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 355 | -42 | -269 | 68 | 183 | 649 | -287 | 413 | 153 | 219 | -22 | 390 |
| Cash from Investing Activity + | -222 | -105 | -684 | 635 | 93 | -147 | 1,471 | -204 | -118 | -138 | -780 | -231 |
| Cash from Financing Activity + | -76 | 193 | 1,254 | -769 | -776 | -680 | -1,171 | -71 | -315 | 334 | 409 | -54 |
| Net Cash Flow | 57 | 46 | 301 | -66 | -500 | -178 | 13 | 138 | -280 | 415 | -393 | 105 |
| Free Cash Flow | -76 | -105 | -678 | -238 | 127 | 486 | -452 | 202 | 23 | 69 | -377 | 76 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 73% | -8% | -1,887% | 4,697% | -583% | 560% | 270% | 171% | 161% | 274% | -13% | 63% |
Financials of Wockhardt
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 60 | 91 | 94 | 89 | 130 | 159 | 124 | 104 | 110 | 81 | 80 | 64 |
| Inventory Days | 250 | 249 | 243 | 174 | 183 | 209 | 256 | 222 | 216 | 201 | 234 | 286 |
| Days Payable | 136 | 144 | 117 | 122 | 187 | 272 | 223 | 265 | 285 | 240 | 191 | 182 |
| Cash Conversion Cycle | 175 | 196 | 220 | 141 | 126 | 97 | 157 | 60 | 41 | 41 | 123 | 168 |
| Working Capital Days | 14 | 52 | 36 | -56 | -51 | -171 | -133 | -116 | -186 | -163 | -23 | 35 |
| ROCE % | 10% | 7% | -1% | -1% | -1% | -1% | -3% | 1% | -0% | -1% | 4% | 8% |
Guidance history
How Wockhardt's guidance has moved, call by call
| Call | Revenue | Margins | Capex | Fundraising | Order book |
|---|---|---|---|---|---|
| Q4 FY26 call → | 20–40% | Flat | Planned | — | — |
| Q4 FY25 call → | 20–40% | Flat | Planned | Planned | — |
| Q3 FY23 call → | 20–40% | Up 2%+ | Planned | Planned | — |
What management guided on each call, newest first. Not investment advice, and not a forecast of returns.
Momentum score · price trend
75 out of 100 — Strengthening
Over the past year its share price has done better than most of the stocks we track.
| Period | Share price change | Better than … of 1,920 stocks |
|---|---|---|
| Last 12 months | +43.9% | 82% |
| Last 6 months | +21.2% | 77% |
| Last 3 months | −3.7% | 55% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,920 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Wockhardt: 0.4 × 82 + 0.4 × 77 + 0.2 × 55 = 75.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 6 Nov 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Wockhardt's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q3 FY24 earnings call analysis →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- Divis Laboratories (Q2 FY27)
Consolidated total income: ₹3770 crores . Key results statement takeaways from Divis Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sec
- Infinium Pharma (Q2 FY27)
3,940.98 Lacs (about 54.3% increase) . Key results statement takeaways from Infinium Pharmachem Ltd's Q2 FY27 results statement — and how it ranks against secto
- Walpar Nutrition (Q2 FY27)
3,631.14 Lakhs for the half year ended September 30, 2025, reflecting a year-on-year increase of approximately 13.79%. Key results statement takeaways from Walp
- Kilitch Drugs (Q2 FY27)
14.3%) . Key results statement takeaways from Kilitch Drugs (India) Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
